# US 2022/0031856 A1 · Conjugates of tumor necrosis factor inhibitors to functionalized polymers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031856 A1
- Document ID: US20220031856A1
- Status: Published application
- Kind: A1
- Application number: 17/198,987
- Filed: 2021-03-11
- Published: 2022-02-03
- Earliest claimed: 2012-06-12
- Assignees: QuiaPEG Pharmaceuticals AB
- Applicants: QuiaPEG Pharmaceuticals AB
- Inventors: Marek Kwiatkowski
- Web page: https://patentgrep.com/patent/US20220031856A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/28: Insulins
- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61K 38/37: Factors VIII
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 38/4866: {Protein C (3.4.21.69)}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/39566: {against immunoglobulins, e.g. anti-idiotypic antibodies}
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61P 11/06: Antiasthmatics
- C07K 1/1077: {by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
- C07K 14/62: Insulins
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/4291: {against IgE}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 9/2462: {Lysozyme (3.2.1.17)}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12Y 302/01017: Lysozyme (3.2.1.17)
- A61K 2039/505: {comprising antibodies}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of making a TNF inhibitor conjugate, said method comprising reacting a TNF inhibitor with a preparation comprising a compound of formula (2) under conditions suitable for group M or R to react with said TNF inhibitor:
or a salt form thereof,
wherein:
polymer is a linear, water-soluble, non-peptidic, and non-nucleotidic polymer backbone, wherein each linking group is bonded at a different terminus of said polymer;
E and E1 are independently O or S;
K and K1 are independently selected from the group consisting of: alkylene, alkyleneoxyalkylene, and oligomeric alkyleneoxyalkylene;
G and G1 are independently absent or are selected from the group consisting of: alkoxy and a hydrophobic separation handle;
each pair of Z1 and Z2 and Z3 and Z4 are independently selected from O and NIT, wherein only one of each pair of Z1 and Z2 and Z3 and Z4 can be NH;
L and L1 are independently selected from the group consisting of: a divalent radical of a nucleoside, alkylene, alkyleneoxyalkylene, oligomeric alkyleneoxyalkylene, and unsubstituted or substituted arylene;
M and M1 are independently selected from a protected group that when deprotected is reactive with the TNF inhibitor or a group reactive with the TNF inhibitor, wherein M and M1 are different; and
R and R1 are independently absent, hydrogen, a protecting group, or an activating group;
wherein when M is a protected group that when deprotected is reactive with the TNF inhibitor, then R is a protecting group or a hydrophobic separation handle;
wherein when M is a group reactive with the TNF inhibitor, R is absent, hydrogen, or an activating group;
wherein when M1 is a protected group that when deprotected is reactive with the TNF inhibitor, then R1 is a protecting group or a hydrophobic separation handle; and
wherein when M1 is a group reactive with the TNF inhibitor, R1 is absent, hydrogen, or an activating group.

### Claim 3 (depends on 2)

The method of claim 2, wherein said polymer backbone is selected from the group consisting of poly(alkylene glycol), poly(oxyethylated polyol), poly(olefinic alcohol), poly(α-hydroxy acid), poly(vinyl alcohol), polyoxazoline, and copolymers.

### Claim 4 (depends on 2)

The method of claim 2, wherein said polymer backbone is poly(ethylene glycol).

### Claim 5 (depends on 2)

The method of claim 2, wherein said poly(ethylene glycol) has an average molecular weight from about 500 Da to about 100,000 Da.

### Claim 6 (depends on 2)

The method of claim 2, wherein E is O.

### Claim 7 (depends on 2)

The method of claim 2, wherein E1 is O.

### Claim 8 (depends on 2)

The method of claim 2, wherein Z1 is O and Z2 is NH.

### Claim 9 (depends on 2)

The method of claim 2, wherein both Z1 and Z2 are O.

### Claim 10 (depends on 2)

The method of claim 2, wherein Z3 is O and Z4 is NH.

### Claim 11 (depends on 2)

The method of claim 2, wherein both Z3 and Z4 are O.

### Claim 12 (depends on 2)

The method of claim 2, wherein K is selected from the group consisting of: methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, tert-butylene, and hexylene, or a residue from diethylene glycol, triethylene glycol, tetraethylene glycol or hexaethylene glycol.

### Claim 13 (depends on 2)

The method of claim 2, wherein K1 is selected from the group consisting of: methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, tert-butylene, and hexylene, or a residue from diethylene glycol, triethylene glycol, tetraethylene glycol or hexaethylene glycol.

### Claim 14 (depends on 2)

The method of claim 2, wherein G is a substituted or unsubstituted trityloxy.

### Claim 15 (depends on 2)

The method of claim 2, wherein G1 is a substituted or unsubstituted trityloxy.

### Claim 16 (depends on 2)

The method of claim 2, wherein L is a substituted or unsubstituted C1-C12 alkylene.

### Claim 17 (depends on 2)

The method of claim 2, wherein L1 is a substituted or unsubstituted C1-C12 alkylene.

### Claim 18 (depends on 2)

The method of claim 2, wherein M, when deprotected, is selected from the group consisting of: hydroxyl, amine, thiol, carboxyl, aldehyde, glyoxal, dione, alkenyl, alkynyl, alkedienyl, azide, acrylamide, vinyl sulfone, hydrazide, aminoxy, maleimide, dithiopyridine, and iodoacetamide.

### Claim 19 (depends on 2)

The method of claim 2, wherein M1, when deprotected, is selected from the group consisting of: hydroxyl, amine, thiol, carboxyl, aldehyde, glyoxal, dione, alkenyl, alkynyl, alkedienyl, azide, acrylamide, vinyl sulfone, hydrazide, aminoxy, maleimide, dithiopyridine, and iodoacetamide.

### Claim 20 (depends on 2)

The method of claim 2, wherein said TNF inhibitor is selected from the group consisting of a fusion protein, a monoclonal antibody, and an antibody fragment.

### Claim 21 (depends on 2)

The method of claim 2, wherein said TNF inhibitor is selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab.
